Establishment and characterization of a novel cell line, NCC-MFS1-C1, derived from a patient with myxofibrosarcoma

Myxofibrosarcoma (MFS) is an aggressive sarcoma that requires novel therapeutic approaches to improve its clinical outcome. Cell lines are a valuable tool for pre-clinical research; however, there is a lack of patient-derived cell lines of MFS available from public cell banks. This study aimed to de...

Full description

Saved in:
Bibliographic Details
Published inHuman cell : official journal of Human Cell Research Society Vol. 32; no. 2; pp. 214 - 222
Main Authors Kito, Fusako, Oyama, Rieko, Sakumoto, Marimu, Shiozawa, Kumiko, Qiao, Zhiwei, Toki, Shunichi, Yoshida, Akihiko, Kawai, Akira, Kondo, Tadashi
Format Journal Article
LanguageEnglish
Published Tokyo Springer Japan 01.04.2019
Springer Nature B.V
Subjects
Biomedical and Life Sciences
Cell Biology
Cell culture
Drug development
Drug screening
Gynecology
Life Sciences
Oncology
Proteomics
Reproductive Medicine
Research Article
Sarcoma
Stem Cells
Surgery
Myxofibrosarcoma
Cell line
Drug screening
Proteomics
Online AccessGet full text

Cover

More Information
Summary:Myxofibrosarcoma (MFS) is an aggressive sarcoma that requires novel therapeutic approaches to improve its clinical outcome. Cell lines are a valuable tool for pre-clinical research; however, there is a lack of patient-derived cell lines of MFS available from public cell banks. This study aimed to develop a patient-derived cell line of MFS. A cell line designated NCC-MFS1-C1 was established from the primary tumor tissue of an 82-year-old male patient with MFS. The short tandem repeat pattern of NCC-MFS1-C1 cells was identical to that of the original tumor, but distinct from that of any other cell lines in public cell banks. NCC-MFS1-C1 cells were maintained as a monolayer culture for over 20 passages in 19 months; the cells exhibited spindle-like morphology, continuous growth, and ability for spheroid formation and invasion. Genomic assay showed that NCC-MFS1-C1 cells had gain and loss of genetic loci. Proteomic profiling revealed that the original tumor and the derived NCC-MFS1-C1 cells had similar, but distinct protein expression patterns. Screening of anti-cancer drugs in NCC-MFS1-C1 cells identified five candidate drugs for MFS. In conclusion, we established a novel MFS cell line, NCC-MFS1-C1, which could be used to study tumor development and effects of anti-cancer drugs.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:1749-0774
0914-7470
1749-0774
DOI:10.1007/s13577-018-00233-1